Navigation Links
EntreMed to Present at the New York Society of Security Analysts Industry Conference
Date:11/25/2008

ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at www.entremed.com.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's we
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
2. EntreMed Reports Third Quarter 2008 Financial Results
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. EntreMed to Present at BioPartnering Europe Conference
5. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
6. EntreMed Reports Second Quarter 2008 Financial Results
7. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
8. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
9. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Receives Nasdaq Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Special Protocol Assessment with the Food and ... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on oncology and ... its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( ... trial for perifosine (KRX-0401), the Company,s PI3K/Akt ...
(Date:12/15/2009)... Calif., Dec. 15 Epeius Biotechnologies Corporation, ... genetic medicine, gained international validation of the cutting-edge ... , when scientists around the world rediscovered the ... major locus of cancer pathogenesis and disease progression, ... Recently, scientists at the NIH National Cancer Institute ...
(Date:12/15/2009)... Medical, Inc. (OTC Bulletin Board : AEMD) announced ... Comper have joined the Science Advisory ... Schorey and Dr. Comper are leading researchers in ... of Aethlon Medical, was recently formed to leverage ... being advanced as an adjunct therapy for Hepatitis-C ...
(Date:12/15/2009)... The Center for Business Intelligence (CBI), a ... announce the full agenda for the ... . The forum will take place at ... ,, Over 1,500 senior-level Finance, Accounting, Audit ... event since its inception, and this year,s ...
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2
... Life Sciences,Greenhouse (PLSG), the private/public partnership putting ... track for growth, announced that Peter M.,DeComo, ... Inc., John,A. Kuzmishin, Vice President of Strategic ... Chief Executive Officer, Respironics, and,Elizabeth S. Woo, ...
... throughput ... and walk-away time -, HOPKINTON, Mass., ... launched a new high throughput RNA,assay for automatically assessing the concentration, ... expected by the,research community, was launched on schedule and runs in ...
... stem cell therapy market to grow rapidly ... over next decade, WALTHAM, ... the stem cell therapy market in,its US Markets for Stem Cell Therapies 2007 ... its infancy, it will,grow rapidly as products are approved in the US. Today, ...
Other Biology Technology:The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 2The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors 3Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies 2Stem Cell Therapy to Skyrocket by 2017 2
(Date:12/14/2009)... use as a defining feature of humans. That,s until examples ... birds and an array of other mammals. Now, a report ... a Cell Press publication, adds an octopus to the growing ... manages a behavioral trick that the researchers call stilt walking. ... coconut shell "bowls," makes its eight arms rigid, and raises ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
(Date:12/11/2009)... consumer demand for premium fruit increases, growers are ... market. And to boost their bottom line, orchard ... increase fruit quality while reducing labor costs. , ... to produce larger, healthier fruit, is among the ... impact on fruit production overhead, and, ultimately, prices ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Horizontal string trimmer reduces labor costs, increases peach size 2WAV Distribution Partners with Vecima Networks Inc 60866 1WAV Distribution Partners with Vecima Networks Inc 60866 2WAV Distribution Partners with Vecima Networks Inc 60866 3Father Norman Weslin and Four Pro Lifers Still in Jail 60863 1Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 60860 1Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 60860 2Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 60860 3
... how the brain controls breathing is fundamental to the ... an automatic rhythmic process that persists without conscious effort ... that has intrigued many scientists for well over 100 ... rhythm throughout life? , Experimental Physiology editor Julian Paton ...
... Medical School (HMS) have revealed details of a key step ... work, which grew out of an ongoing effort to produce ... of the bacterial toxin plays an active role in transferring ... membrane. , The research, led by R. John Collier, professor ...
... Services University of the Health Sciences (USU), the ... Cancer Institute (NCI) have made a major breakthrough ... could be engineered for use as bioweapons. The ... and Hendra viruses--naturally occurring and highly pathogenic paramyxoviruses ...
Other Biology News:How exactly does the brain control breathing? 2Critical step traced in anthrax infection 2Discovery could be key to bioterrorism defense 2Discovery could be key to bioterrorism defense 3
... II Informatix dimensioning ... optional module that ... analysis, multidimensional scaling, ... MANOVA, and self-organizing ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
... gel marker mix was designed specifically to aid ... contains a complement of seven reduced and denatured ... those who use markers to assess 2-D system ... of proteins undergoing 2-D separation and analysis. , ...
... consist of seven reduced, denatured proteins (equine ... rabbit muscle GAPDH, bovine muscle actin, BSA, ... ranging from 4.5 to 8.5 and molecular ... 2-D standards provide calibrated references for the ...
Biology Products: